Certain drugs are associated with weight gain, including some antipsychotics (olanzapine, quetiapine), mood stabilisers (sodium valproate, lithium), antidepressants (mirtazapine, some tricyclics), corticosteroids, insulin, sulfonylureas, and beta-blockers
An alternative trial enrolled adults who have type 2 diabetes
Originally developed by Eli Lilly, it is FDA-approved as Mounjaro (for diabetes) and Zepbound (for weight management)
Food and beverage category impact by GLP-1 users Beyond food groups, the impact of GLP-1 is also influencing consumer packaged goods (CPGs) and ingredient companies
Slowed gastric emptying: By delaying stomach emptying, GLP-1 RAs increase feelings of fullness and reduce meal size